nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—CYP1A2—Carmustine—lymphatic system cancer	0.08	1	CbGbCtD
Frovatriptan—Dehydration—Mitoxantrone—lymphatic system cancer	0.0036	0.00391	CcSEcCtD
Frovatriptan—Dysphagia—Carmustine—lymphatic system cancer	0.0036	0.00391	CcSEcCtD
Frovatriptan—Stomatitis—Bleomycin—lymphatic system cancer	0.00358	0.00389	CcSEcCtD
Frovatriptan—Tachycardia—Teniposide—lymphatic system cancer	0.00355	0.00386	CcSEcCtD
Frovatriptan—Malaise—Fludarabine—lymphatic system cancer	0.00353	0.00384	CcSEcCtD
Frovatriptan—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00351	0.00382	CcSEcCtD
Frovatriptan—Muscular weakness—Vincristine—lymphatic system cancer	0.0035	0.00381	CcSEcCtD
Frovatriptan—Pruritus—Mechlorethamine—lymphatic system cancer	0.00349	0.00379	CcSEcCtD
Frovatriptan—Anorexia—Teniposide—lymphatic system cancer	0.00347	0.00377	CcSEcCtD
Frovatriptan—Convulsion—Fludarabine—lymphatic system cancer	0.00339	0.00369	CcSEcCtD
Frovatriptan—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00337	0.00367	CcSEcCtD
Frovatriptan—Myalgia—Fludarabine—lymphatic system cancer	0.00333	0.00362	CcSEcCtD
Frovatriptan—Arthralgia—Fludarabine—lymphatic system cancer	0.00333	0.00362	CcSEcCtD
Frovatriptan—Haemoglobin—Bleomycin—lymphatic system cancer	0.00331	0.0036	CcSEcCtD
Frovatriptan—Haemorrhage—Bleomycin—lymphatic system cancer	0.0033	0.00358	CcSEcCtD
Frovatriptan—Discomfort—Fludarabine—lymphatic system cancer	0.00329	0.00358	CcSEcCtD
Frovatriptan—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00328	0.00357	CcSEcCtD
Frovatriptan—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00326	0.00354	CcSEcCtD
Frovatriptan—Dyspnoea—Teniposide—lymphatic system cancer	0.00324	0.00352	CcSEcCtD
Frovatriptan—Confusional state—Fludarabine—lymphatic system cancer	0.00322	0.0035	CcSEcCtD
Frovatriptan—Depression—Carmustine—lymphatic system cancer	0.0032	0.00347	CcSEcCtD
Frovatriptan—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00319	0.00347	CcSEcCtD
Frovatriptan—Decreased appetite—Teniposide—lymphatic system cancer	0.00316	0.00343	CcSEcCtD
Frovatriptan—Vomiting—Mechlorethamine—lymphatic system cancer	0.00314	0.00341	CcSEcCtD
Frovatriptan—Stomatitis—Carmustine—lymphatic system cancer	0.00313	0.0034	CcSEcCtD
Frovatriptan—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00309	0.00336	CcSEcCtD
Frovatriptan—Speech disorder—Methotrexate—lymphatic system cancer	0.00309	0.00335	CcSEcCtD
Frovatriptan—Flushing—Bleomycin—lymphatic system cancer	0.00306	0.00333	CcSEcCtD
Frovatriptan—Depression—Vincristine—lymphatic system cancer	0.00305	0.00332	CcSEcCtD
Frovatriptan—Anorexia—Fludarabine—lymphatic system cancer	0.00305	0.00331	CcSEcCtD
Frovatriptan—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00302	0.00328	CcSEcCtD
Frovatriptan—Myocardial infarction—Vincristine—lymphatic system cancer	0.003	0.00326	CcSEcCtD
Frovatriptan—Feeling abnormal—Teniposide—lymphatic system cancer	0.003	0.00326	CcSEcCtD
Frovatriptan—Stomatitis—Vincristine—lymphatic system cancer	0.00298	0.00324	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00297	0.00323	CcSEcCtD
Frovatriptan—Chills—Bleomycin—lymphatic system cancer	0.00296	0.00322	CcSEcCtD
Frovatriptan—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00294	0.00319	CcSEcCtD
Frovatriptan—Nausea—Mechlorethamine—lymphatic system cancer	0.00293	0.00318	CcSEcCtD
Frovatriptan—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00292	0.00318	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00291	0.00316	CcSEcCtD
Frovatriptan—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00291	0.00316	CcSEcCtD
Frovatriptan—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.0029	0.00315	CcSEcCtD
Frovatriptan—Haemoglobin—Carmustine—lymphatic system cancer	0.00289	0.00314	CcSEcCtD
Frovatriptan—Haemorrhage—Carmustine—lymphatic system cancer	0.00288	0.00313	CcSEcCtD
Frovatriptan—Abdominal pain—Teniposide—lymphatic system cancer	0.00287	0.00312	CcSEcCtD
Frovatriptan—Body temperature increased—Teniposide—lymphatic system cancer	0.00287	0.00312	CcSEcCtD
Frovatriptan—Paraesthesia—Fludarabine—lymphatic system cancer	0.00287	0.00312	CcSEcCtD
Frovatriptan—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00286	0.00311	CcSEcCtD
Frovatriptan—Dyspnoea—Fludarabine—lymphatic system cancer	0.00285	0.0031	CcSEcCtD
Frovatriptan—Dyspepsia—Fludarabine—lymphatic system cancer	0.00281	0.00306	CcSEcCtD
Frovatriptan—Sinusitis—Mitoxantrone—lymphatic system cancer	0.0028	0.00304	CcSEcCtD
Frovatriptan—Decreased appetite—Fludarabine—lymphatic system cancer	0.00278	0.00302	CcSEcCtD
Frovatriptan—Visual impairment—Carmustine—lymphatic system cancer	0.00277	0.00301	CcSEcCtD
Frovatriptan—Fatigue—Fludarabine—lymphatic system cancer	0.00275	0.00299	CcSEcCtD
Frovatriptan—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00273	0.00297	CcSEcCtD
Frovatriptan—Pain—Fludarabine—lymphatic system cancer	0.00273	0.00297	CcSEcCtD
Frovatriptan—Constipation—Fludarabine—lymphatic system cancer	0.00273	0.00297	CcSEcCtD
Frovatriptan—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00272	0.00296	CcSEcCtD
Frovatriptan—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00271	0.00295	CcSEcCtD
Frovatriptan—Urethral disorder—Vincristine—lymphatic system cancer	0.00269	0.00293	CcSEcCtD
Frovatriptan—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00269	0.00292	CcSEcCtD
Frovatriptan—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00268	0.00292	CcSEcCtD
Frovatriptan—Hypersensitivity—Teniposide—lymphatic system cancer	0.00268	0.00291	CcSEcCtD
Frovatriptan—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00268	0.00291	CcSEcCtD
Frovatriptan—Flushing—Carmustine—lymphatic system cancer	0.00267	0.0029	CcSEcCtD
Frovatriptan—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00266	0.00289	CcSEcCtD
Frovatriptan—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00266	0.00289	CcSEcCtD
Frovatriptan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00263	0.00286	CcSEcCtD
Frovatriptan—Asthenia—Teniposide—lymphatic system cancer	0.00261	0.00283	CcSEcCtD
Frovatriptan—Malaise—Bleomycin—lymphatic system cancer	0.00259	0.00281	CcSEcCtD
Frovatriptan—Pruritus—Teniposide—lymphatic system cancer	0.00257	0.0028	CcSEcCtD
Frovatriptan—Arrhythmia—Carmustine—lymphatic system cancer	0.00257	0.00279	CcSEcCtD
Frovatriptan—Body temperature increased—Fludarabine—lymphatic system cancer	0.00253	0.00275	CcSEcCtD
Frovatriptan—Mental disorder—Carmustine—lymphatic system cancer	0.00252	0.00274	CcSEcCtD
Frovatriptan—Malnutrition—Carmustine—lymphatic system cancer	0.00251	0.00272	CcSEcCtD
Frovatriptan—Diarrhoea—Teniposide—lymphatic system cancer	0.00249	0.0027	CcSEcCtD
Frovatriptan—Myalgia—Bleomycin—lymphatic system cancer	0.00244	0.00266	CcSEcCtD
Frovatriptan—Chest pain—Bleomycin—lymphatic system cancer	0.00244	0.00266	CcSEcCtD
Frovatriptan—Back pain—Carmustine—lymphatic system cancer	0.00242	0.00263	CcSEcCtD
Frovatriptan—Discomfort—Bleomycin—lymphatic system cancer	0.00241	0.00262	CcSEcCtD
Frovatriptan—Mental disorder—Vincristine—lymphatic system cancer	0.00241	0.00262	CcSEcCtD
Frovatriptan—Chills—Mitoxantrone—lymphatic system cancer	0.0024	0.00261	CcSEcCtD
Frovatriptan—Urine output increased—Methotrexate—lymphatic system cancer	0.0024	0.00261	CcSEcCtD
Frovatriptan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00239	0.0026	CcSEcCtD
Frovatriptan—Confusional state—Bleomycin—lymphatic system cancer	0.00236	0.00257	CcSEcCtD
Frovatriptan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00235	0.00256	CcSEcCtD
Frovatriptan—Tremor—Carmustine—lymphatic system cancer	0.00235	0.00255	CcSEcCtD
Frovatriptan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00234	0.00255	CcSEcCtD
Frovatriptan—Back pain—Vincristine—lymphatic system cancer	0.00231	0.00251	CcSEcCtD
Frovatriptan—Vomiting—Teniposide—lymphatic system cancer	0.00231	0.00251	CcSEcCtD
Frovatriptan—Agitation—Carmustine—lymphatic system cancer	0.0023	0.0025	CcSEcCtD
Frovatriptan—Asthenia—Fludarabine—lymphatic system cancer	0.00229	0.00249	CcSEcCtD
Frovatriptan—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00228	0.00248	CcSEcCtD
Frovatriptan—Headache—Teniposide—lymphatic system cancer	0.00228	0.00248	CcSEcCtD
Frovatriptan—Pruritus—Fludarabine—lymphatic system cancer	0.00226	0.00246	CcSEcCtD
Frovatriptan—Back pain—Mitoxantrone—lymphatic system cancer	0.00225	0.00245	CcSEcCtD
Frovatriptan—Anorexia—Bleomycin—lymphatic system cancer	0.00223	0.00243	CcSEcCtD
Frovatriptan—Agitation—Vincristine—lymphatic system cancer	0.0022	0.00239	CcSEcCtD
Frovatriptan—Polyuria—Methotrexate—lymphatic system cancer	0.00219	0.00239	CcSEcCtD
Frovatriptan—Diarrhoea—Fludarabine—lymphatic system cancer	0.00219	0.00238	CcSEcCtD
Frovatriptan—Convulsion—Carmustine—lymphatic system cancer	0.00217	0.00236	CcSEcCtD
Frovatriptan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00216	0.00235	CcSEcCtD
Frovatriptan—Nausea—Teniposide—lymphatic system cancer	0.00216	0.00235	CcSEcCtD
Frovatriptan—Vertigo—Vincristine—lymphatic system cancer	0.00215	0.00234	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00213	0.00232	CcSEcCtD
Frovatriptan—Myalgia—Carmustine—lymphatic system cancer	0.00213	0.00232	CcSEcCtD
Frovatriptan—Chest pain—Carmustine—lymphatic system cancer	0.00213	0.00232	CcSEcCtD
Frovatriptan—Anxiety—Carmustine—lymphatic system cancer	0.00213	0.00231	CcSEcCtD
Frovatriptan—Paraesthesia—Bleomycin—lymphatic system cancer	0.0021	0.00229	CcSEcCtD
Frovatriptan—Malaise—Mitoxantrone—lymphatic system cancer	0.0021	0.00228	CcSEcCtD
Frovatriptan—Dyspnoea—Bleomycin—lymphatic system cancer	0.00209	0.00227	CcSEcCtD
Frovatriptan—Convulsion—Vincristine—lymphatic system cancer	0.00207	0.00225	CcSEcCtD
Frovatriptan—Confusional state—Carmustine—lymphatic system cancer	0.00206	0.00224	CcSEcCtD
Frovatriptan—Decreased appetite—Bleomycin—lymphatic system cancer	0.00204	0.00221	CcSEcCtD
Frovatriptan—Myalgia—Vincristine—lymphatic system cancer	0.00204	0.00221	CcSEcCtD
Frovatriptan—Vomiting—Fludarabine—lymphatic system cancer	0.00203	0.00221	CcSEcCtD
Frovatriptan—Convulsion—Mitoxantrone—lymphatic system cancer	0.00202	0.00219	CcSEcCtD
Frovatriptan—Pain—Bleomycin—lymphatic system cancer	0.002	0.00218	CcSEcCtD
Frovatriptan—Headache—Fludarabine—lymphatic system cancer	0.002	0.00218	CcSEcCtD
Frovatriptan—Tachycardia—Carmustine—lymphatic system cancer	0.002	0.00217	CcSEcCtD
Frovatriptan—Chest pain—Mitoxantrone—lymphatic system cancer	0.00198	0.00216	CcSEcCtD
Frovatriptan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00198	0.00216	CcSEcCtD
Frovatriptan—Myalgia—Mitoxantrone—lymphatic system cancer	0.00198	0.00216	CcSEcCtD
Frovatriptan—Anxiety—Mitoxantrone—lymphatic system cancer	0.00198	0.00215	CcSEcCtD
Frovatriptan—Discomfort—Mitoxantrone—lymphatic system cancer	0.00196	0.00213	CcSEcCtD
Frovatriptan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00195	0.00212	CcSEcCtD
Frovatriptan—Anorexia—Carmustine—lymphatic system cancer	0.00195	0.00212	CcSEcCtD
Frovatriptan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00193	0.0021	CcSEcCtD
Frovatriptan—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00193	0.00209	CcSEcCtD
Frovatriptan—Confusional state—Mitoxantrone—lymphatic system cancer	0.00192	0.00208	CcSEcCtD
Frovatriptan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0019	0.00207	CcSEcCtD
Frovatriptan—Nausea—Fludarabine—lymphatic system cancer	0.0019	0.00206	CcSEcCtD
Frovatriptan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00189	0.00205	CcSEcCtD
Frovatriptan—Shock—Mitoxantrone—lymphatic system cancer	0.00187	0.00203	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00186	0.00202	CcSEcCtD
Frovatriptan—Anorexia—Vincristine—lymphatic system cancer	0.00186	0.00202	CcSEcCtD
Frovatriptan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00186	0.00202	CcSEcCtD
Frovatriptan—Body temperature increased—Bleomycin—lymphatic system cancer	0.00185	0.00201	CcSEcCtD
Frovatriptan—Insomnia—Carmustine—lymphatic system cancer	0.00185	0.00201	CcSEcCtD
Frovatriptan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00184	0.002	CcSEcCtD
Frovatriptan—Paraesthesia—Carmustine—lymphatic system cancer	0.00184	0.002	CcSEcCtD
Frovatriptan—Mood swings—Methotrexate—lymphatic system cancer	0.00183	0.00198	CcSEcCtD
Frovatriptan—Dyspnoea—Carmustine—lymphatic system cancer	0.00182	0.00198	CcSEcCtD
Frovatriptan—Somnolence—Carmustine—lymphatic system cancer	0.00182	0.00198	CcSEcCtD
Frovatriptan—Anorexia—Mitoxantrone—lymphatic system cancer	0.00181	0.00197	CcSEcCtD
Frovatriptan—Ataxia—Methotrexate—lymphatic system cancer	0.00181	0.00197	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00178	0.00193	CcSEcCtD
Frovatriptan—Decreased appetite—Carmustine—lymphatic system cancer	0.00178	0.00193	CcSEcCtD
Frovatriptan—Insomnia—Vincristine—lymphatic system cancer	0.00177	0.00192	CcSEcCtD
Frovatriptan—Paraesthesia—Vincristine—lymphatic system cancer	0.00175	0.00191	CcSEcCtD
Frovatriptan—Constipation—Carmustine—lymphatic system cancer	0.00175	0.0019	CcSEcCtD
Frovatriptan—Pain—Carmustine—lymphatic system cancer	0.00175	0.0019	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00173	0.00188	CcSEcCtD
Frovatriptan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00173	0.00188	CcSEcCtD
Frovatriptan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00171	0.00186	CcSEcCtD
Frovatriptan—Decreased appetite—Vincristine—lymphatic system cancer	0.0017	0.00184	CcSEcCtD
Frovatriptan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00169	0.00184	CcSEcCtD
Frovatriptan—Somnolence—Mitoxantrone—lymphatic system cancer	0.00169	0.00184	CcSEcCtD
Frovatriptan—Feeling abnormal—Carmustine—lymphatic system cancer	0.00169	0.00183	CcSEcCtD
Frovatriptan—Fatigue—Vincristine—lymphatic system cancer	0.00168	0.00183	CcSEcCtD
Frovatriptan—Asthenia—Bleomycin—lymphatic system cancer	0.00168	0.00183	CcSEcCtD
Frovatriptan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00167	0.00182	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00167	0.00182	CcSEcCtD
Frovatriptan—Constipation—Vincristine—lymphatic system cancer	0.00167	0.00181	CcSEcCtD
Frovatriptan—Pain—Vincristine—lymphatic system cancer	0.00167	0.00181	CcSEcCtD
Frovatriptan—Pruritus—Bleomycin—lymphatic system cancer	0.00166	0.0018	CcSEcCtD
Frovatriptan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00165	0.0018	CcSEcCtD
Frovatriptan—Fatigue—Mitoxantrone—lymphatic system cancer	0.00164	0.00178	CcSEcCtD
Frovatriptan—Constipation—Mitoxantrone—lymphatic system cancer	0.00163	0.00177	CcSEcCtD
Frovatriptan—Pain—Mitoxantrone—lymphatic system cancer	0.00163	0.00177	CcSEcCtD
Frovatriptan—Abdominal pain—Carmustine—lymphatic system cancer	0.00162	0.00176	CcSEcCtD
Frovatriptan—Body temperature increased—Carmustine—lymphatic system cancer	0.00162	0.00176	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.0016	0.00173	CcSEcCtD
Frovatriptan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00157	0.0017	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00155	0.00169	CcSEcCtD
Frovatriptan—Abdominal pain—Vincristine—lymphatic system cancer	0.00154	0.00168	CcSEcCtD
Frovatriptan—Body temperature increased—Vincristine—lymphatic system cancer	0.00154	0.00168	CcSEcCtD
Frovatriptan—Hypersensitivity—Carmustine—lymphatic system cancer	0.00151	0.00164	CcSEcCtD
Frovatriptan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0015	0.00163	CcSEcCtD
Frovatriptan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0015	0.00163	CcSEcCtD
Frovatriptan—Vomiting—Bleomycin—lymphatic system cancer	0.00149	0.00162	CcSEcCtD
Frovatriptan—Depression—Methotrexate—lymphatic system cancer	0.00148	0.00161	CcSEcCtD
Frovatriptan—Asthenia—Carmustine—lymphatic system cancer	0.00147	0.00159	CcSEcCtD
Frovatriptan—Stomatitis—Methotrexate—lymphatic system cancer	0.00145	0.00157	CcSEcCtD
Frovatriptan—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00144	0.00157	CcSEcCtD
Frovatriptan—Hypersensitivity—Vincristine—lymphatic system cancer	0.00144	0.00156	CcSEcCtD
Frovatriptan—Epistaxis—Methotrexate—lymphatic system cancer	0.0014	0.00152	CcSEcCtD
Frovatriptan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.0014	0.00152	CcSEcCtD
Frovatriptan—Asthenia—Vincristine—lymphatic system cancer	0.0014	0.00152	CcSEcCtD
Frovatriptan—Diarrhoea—Carmustine—lymphatic system cancer	0.0014	0.00152	CcSEcCtD
Frovatriptan—Nausea—Bleomycin—lymphatic system cancer	0.00139	0.00151	CcSEcCtD
Frovatriptan—Asthenia—Mitoxantrone—lymphatic system cancer	0.00136	0.00148	CcSEcCtD
Frovatriptan—Dizziness—Carmustine—lymphatic system cancer	0.00135	0.00147	CcSEcCtD
Frovatriptan—Haemoglobin—Methotrexate—lymphatic system cancer	0.00134	0.00146	CcSEcCtD
Frovatriptan—Diarrhoea—Vincristine—lymphatic system cancer	0.00134	0.00145	CcSEcCtD
Frovatriptan—Haemorrhage—Methotrexate—lymphatic system cancer	0.00133	0.00145	CcSEcCtD
Frovatriptan—Pharyngitis—Methotrexate—lymphatic system cancer	0.00132	0.00144	CcSEcCtD
Frovatriptan—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00132	0.00143	CcSEcCtD
Frovatriptan—Urethral disorder—Methotrexate—lymphatic system cancer	0.00131	0.00142	CcSEcCtD
Frovatriptan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0013	0.00141	CcSEcCtD
Frovatriptan—Vomiting—Carmustine—lymphatic system cancer	0.0013	0.00141	CcSEcCtD
Frovatriptan—Dizziness—Vincristine—lymphatic system cancer	0.00129	0.0014	CcSEcCtD
Frovatriptan—Visual impairment—Methotrexate—lymphatic system cancer	0.00128	0.0014	CcSEcCtD
Frovatriptan—Headache—Carmustine—lymphatic system cancer	0.00128	0.00139	CcSEcCtD
Frovatriptan—Tinnitus—Methotrexate—lymphatic system cancer	0.00124	0.00135	CcSEcCtD
Frovatriptan—Vomiting—Vincristine—lymphatic system cancer	0.00124	0.00135	CcSEcCtD
Frovatriptan—Headache—Vincristine—lymphatic system cancer	0.00122	0.00133	CcSEcCtD
Frovatriptan—Nausea—Carmustine—lymphatic system cancer	0.00121	0.00132	CcSEcCtD
Frovatriptan—Vomiting—Mitoxantrone—lymphatic system cancer	0.00121	0.00131	CcSEcCtD
Frovatriptan—Chills—Methotrexate—lymphatic system cancer	0.0012	0.0013	CcSEcCtD
Frovatriptan—Headache—Mitoxantrone—lymphatic system cancer	0.00119	0.00129	CcSEcCtD
Frovatriptan—Mental disorder—Methotrexate—lymphatic system cancer	0.00117	0.00127	CcSEcCtD
Frovatriptan—Malnutrition—Methotrexate—lymphatic system cancer	0.00116	0.00126	CcSEcCtD
Frovatriptan—Nausea—Vincristine—lymphatic system cancer	0.00116	0.00126	CcSEcCtD
Frovatriptan—Dysgeusia—Methotrexate—lymphatic system cancer	0.00114	0.00124	CcSEcCtD
Frovatriptan—Nausea—Mitoxantrone—lymphatic system cancer	0.00113	0.00123	CcSEcCtD
Frovatriptan—Back pain—Methotrexate—lymphatic system cancer	0.00112	0.00122	CcSEcCtD
Frovatriptan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00108	0.00117	CcSEcCtD
Frovatriptan—Malaise—Methotrexate—lymphatic system cancer	0.00105	0.00114	CcSEcCtD
Frovatriptan—Vertigo—Methotrexate—lymphatic system cancer	0.00104	0.00113	CcSEcCtD
Frovatriptan—Convulsion—Methotrexate—lymphatic system cancer	0.00101	0.00109	CcSEcCtD
Frovatriptan—Arthralgia—Methotrexate—lymphatic system cancer	0.000988	0.00107	CcSEcCtD
Frovatriptan—Myalgia—Methotrexate—lymphatic system cancer	0.000988	0.00107	CcSEcCtD
Frovatriptan—Chest pain—Methotrexate—lymphatic system cancer	0.000988	0.00107	CcSEcCtD
Frovatriptan—Discomfort—Methotrexate—lymphatic system cancer	0.000976	0.00106	CcSEcCtD
Frovatriptan—Confusional state—Methotrexate—lymphatic system cancer	0.000955	0.00104	CcSEcCtD
Frovatriptan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000947	0.00103	CcSEcCtD
Frovatriptan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000916	0.000995	CcSEcCtD
Frovatriptan—Anorexia—Methotrexate—lymphatic system cancer	0.000903	0.000981	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000863	0.000938	CcSEcCtD
Frovatriptan—Insomnia—Methotrexate—lymphatic system cancer	0.000857	0.000931	CcSEcCtD
Frovatriptan—Paraesthesia—Methotrexate—lymphatic system cancer	0.00085	0.000924	CcSEcCtD
Frovatriptan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000844	0.000918	CcSEcCtD
Frovatriptan—Somnolence—Methotrexate—lymphatic system cancer	0.000842	0.000915	CcSEcCtD
Frovatriptan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000834	0.000906	CcSEcCtD
Frovatriptan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000823	0.000895	CcSEcCtD
Frovatriptan—Fatigue—Methotrexate—lymphatic system cancer	0.000817	0.000888	CcSEcCtD
Frovatriptan—Pain—Methotrexate—lymphatic system cancer	0.00081	0.00088	CcSEcCtD
Frovatriptan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00078	0.000848	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000774	0.000842	CcSEcCtD
Frovatriptan—Abdominal pain—Methotrexate—lymphatic system cancer	0.000749	0.000814	CcSEcCtD
Frovatriptan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000749	0.000814	CcSEcCtD
Frovatriptan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000698	0.000758	CcSEcCtD
Frovatriptan—Asthenia—Methotrexate—lymphatic system cancer	0.00068	0.000739	CcSEcCtD
Frovatriptan—Pruritus—Methotrexate—lymphatic system cancer	0.00067	0.000728	CcSEcCtD
Frovatriptan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000648	0.000704	CcSEcCtD
Frovatriptan—Dizziness—Methotrexate—lymphatic system cancer	0.000626	0.000681	CcSEcCtD
Frovatriptan—Vomiting—Methotrexate—lymphatic system cancer	0.000602	0.000655	CcSEcCtD
Frovatriptan—Headache—Methotrexate—lymphatic system cancer	0.000593	0.000645	CcSEcCtD
Frovatriptan—Nausea—Methotrexate—lymphatic system cancer	0.000563	0.000611	CcSEcCtD
